



徐州医科大学附属医院



徐医附院减重代谢外科中心

Outcome of Bariatric Surgery in Chinese Patients with Liver Cirrhosis

Hong Jian

The Affiliated Hospital of Xuzhou Medical University

XXVII Ifso World Congress




Melbourne 2024




Cirrhosis is a complex disease that may result in higher morbidity and mortality after abdominal surgery.

The prevalence of MAFLD (*metabolic dysfunction-associated fatty liver disease*) is 60-80% among patients with obesity. It can rapidly progress to steatohepatitis with liver fibrosis and cirrhosis.




The purpose of our study was to describe the outcome of Chinese bariatric surgery patients with cirrhosis.


Study design



4 centers from China



Retrospective study (n=47)



Jan 2016 – Dec 2023
n=9492



Follow-up: 6, 12 months

Inclusion criteria

- I. Patients Age: 18 – 65 years**
- II. BMI: simple obesity $\geq 32 \text{ kg/m}^2$
or BMI $\geq 27 \text{ kg/m}^2$ and ≥ 1 comorbidity**
- III. History of Liver cirrhosis**
- IV. Unexpected diagnosis of Liver Cirrhosis during surgery**

RESULTS


Baseline characteristics

Baseline characteristics (n = 47)	
Age	38.83±11.86
Gender (Male/Female)	28/19
Body weight (kg)	118.96±19.08
BMI (kg/m ²)	41.12±5.20
Type 2 diabetes	26 (55.32%)
hypertension	18 (38.30%)
Dyslipidemia	20 (42.55%)
Obstructive sleep apnea	23 (48.94%)


Baseline characteristics

Child-Pugh classification (n = 47)	
Child-Pugh classification	
Class A	46 (97.87%)
Class B	1 (2.13%)
Class C	0 (0.00%)

Surgical procedures



Visual assessment of the liver




**History of cirrhosis
preoperatively**


**Relatively
similar**

**Suspected cirrhosis
during surgery**


Pathological results



Occurrence of cirrhosis (n=47)




Causes of liver cirrhosis




Blood chemistry status

	Baseline	12 months	P-value
AST (U/L)	46.21 ± 32.84	24.23 ± 14.60	0.0052*
ALT (U/L)	60.11 ± 46.25	28.21 ± 17.31	0.0036*
Total bilirubin (umol/L)	15.75 ± 7.64	19.59 ± 10.84	0.1619
ALB (g/L)	41.97 ± 3.23	41.84 ± 4.26	0.1717
Prothrombin time	12.00 ± 2.14	11.16 ± 0.44	0.3628
INR	0.98 ± 0.12	1.00 ± 0.13	0.7324
Hb (g/L)	145.09 ± 15.90	137.69 ± 13.93	0.0852
Platelets (mmol/L)	216.76 ± 69.94	198.80 ± 46.82	0.3226
Triglycerides (mmol/L)	1.88 ± 1.31	1.05 ± 0.44	0.0070*
Cholesterol	4.79 ± 1.02	4.42 ± 1.09	0.2010
HDL (mmol/L)	1.01 ± 0.24	1.27 ± 0.23	0.0002*


BMI changes




Fasting blood glucose changes



%TWL,%EWL (6-12 mos)




Comorbidity remissions (1 year)



30-day complications

Complications	Rate (%)
Portal vein thrombosis	1 (2.12%) patient
Gastrointestinal bleeding	1 (2.12%) patient
Abdominal infection	1 (2.12%) patient
Overall Readmission	3 (6.38%) Patients


Discussion



- Due to a small number of malabsorptive surgery cases (e.g. RYGB, SASI,..), the outcome of these procedures could not to be compared. Caution is required when selecting malabsorptive procedures in patients with cirrhosis.

Summary

- ◆ **Bariatric surgery can be performed in patients with unexpected liver cirrhosis with low complications and no mortality.**
- ◆ **No liver decompensation was found one year after surgery.**
- ◆ **LSG appears to be safe in patients with liver cirrhosis.**
- ◆ **Further studies with larger samples and longer follow-ups would be needed.**



XXVII Ifso World Congress



Melbourne 2024



THANK YOU !

XXVII Ifso World Congress



Melbourne 2024